Longview Acquisition Corp. II operates as a blank check company whose purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses; it focuses on targets in the healthcare, industrials, consumer, media, technology, and technology services sectors. The company, founded in 2020 and headquartered in New York, New York, does not have significant ongoing operations apart from seeking and completing an initial business combination. Its securities trade on the NYSE under the ticker LGV for Class A ordinary shares, with warrants designated as LGV-WT. In December 2022, following the termination of a proposed business combination with HeartFlow Holding Inc. and the inability to complete a merger by the extended deadline of September 2023, Longview amended its charter and trust agreement, redeemed substantially all public shares at approximately $10.06 per share totaling over $612 million, suspended trading, commenced delisting proceedings on the NYSE, and proceeded to liquidate and dissolve. As of the latest available updates, the company's Exchange Act registration stands revoked, confirming its liquidated status with no active operations or new strategic developments reported.